Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors ...
Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...
The long-term prospects for these stocks look especially bright.
In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Beam Therapeutics, with a price target of $43.00. Claim 60% off TipRanks Premium for data-backed ...
Shares of gene-editing company Intellia Therapeutics continue to struggle under significant pressure. This follows the U.S. Food and Drug Administration's (FDA) decision to halt the firm's most ...
2hon MSNOpinion
Today’s Atlantic trivia: The bat goes crack (crack, crack)
Test your knowledge—and read our latest stories for a little extra help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback